Trial · NCT05075408
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Responders With an Improvement of Worst Itch Numeric Rating Scale (WI NRS) Greater Than and Equal to (>=) 4 From Baseline at Week 12 | Nemolizumab 30 mg | 38.5 | Percentage of Participants | ||
| Percentage of Responders With an Improvement of Worst Itch Numeric Rating Scale (WI NRS) Greater Than and Equal to (>=) 4 From Baseline at Week 12 | Nemolizumab 60 mg | 47.7 | Percentage of Participants | ||
| Percentage of Responders With an Improvement of Worst Itch Numeric Rating Scale (WI NRS) Greater Than and Equal to (>=) 4 From Baseline at Week 12 | Placebo | 32.4 | Percentage of Participants | ||
| Percentage of Responders With an Improvement of WI NRS >= 3 From Baseline at Week 12 | Nemolizumab 30 mg | 49.3 | Percentage of Participants | ||
| Percentage of Responders With an Improvement of WI NRS >= 3 From Baseline at Week 12 | Nemolizumab 60 mg | 60.6 | Percentage of Participants | ||
| Percentage of Responders With an Improvement of WI NRS >= 3 From Baseline at Week 12 | Placebo | 47.1 | Percentage of Participants | ||
| Percentage of Responders With an Improvement of WI NRS >= 4 From Baseline at Week 4 | Nemolizumab 30 mg | 24.3 | Percentage of Participants | ||
| Percentage of Responders With an Improvement of WI NRS >= 4 From Baseline at Week 4 | Nemolizumab 60 mg | 26.6 | Percentage of Participants | ||
| Percentage of Responders With an Improvement of WI NRS >= 4 From Baseline at Week 4 | Placebo | 7.4 | Percentage of Participants | ||
| Percentage of Responders With an Improvement of Sleep Disturbance Numerical Rating Scale (SD NRS) >= 4 From Baseline at Week 12 | Nemolizumab 30 mg | 27.7 | Percentage of Participants | ||
| Percentage of Responders With an Improvement of Sleep Disturbance Numerical Rating Scale (SD NRS) >= 4 From Baseline at Week 12 | Nemolizumab 60 mg | 42.6 | Percentage of Participants | ||
| Percentage of Responders With an Improvement of Sleep Disturbance Numerical Rating Scale (SD NRS) >= 4 From Baseline at Week 12 | Placebo | 25.3 | Percentage of Participants | ||
| Percentage of Responders With an Improvement of WI NRS >= 3 From Baseline at Week 4 | Nemolizumab 30 mg | 36.5 | Percentage of Participants | ||
| Percentage of Responders With an Improvement of WI NRS >= 3 From Baseline at Week 4 | Nemolizumab 60 mg | 35.0 | Percentage of Participants | ||
| Percentage of Responders With an Improvement of WI NRS >= 3 From Baseline at Week 4 | Placebo | 12.8 | Percentage of Participants | ||
| Percentage of Responders With an Improvement of SD NRS >= 4 From Baseline at Week 4 | Nemolizumab 30 mg | 16.1 | Percentage of Participants | ||
| Percentage of Responders With an Improvement of SD NRS >= 4 From Baseline at Week 4 | Nemolizumab 60 mg | 23.6 | Percentage of Participants | ||
| Percentage of Responders With an Improvement of SD NRS >= 4 From Baseline at Week 4 | Placebo | 2.8 | Percentage of Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05075408/results